These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35186829)

  • 1. Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries.
    Kang B; Yi DY; Choe BH
    Front Pediatr; 2021; 9():809838. PubMed ID: 35186829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.
    Yang HC; Kao JH
    Emerg Microbes Infect; 2014 Sep; 3(9):e64. PubMed ID: 26038757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
    Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New paradigms in hepatitis B management: only diamonds are forever.
    Coffin CS; Lee SS
    Br Med Bull; 2015; 116():79-91. PubMed ID: 26377741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
    J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New horizon for radical cure of chronic hepatitis B virus infection.
    Tajiri K; Shimizu Y
    World J Hepatol; 2016 Jul; 8(21):863-73. PubMed ID: 27478536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus.
    Wang G; Guan J; Khan NU; Li G; Shao J; Zhou Q; Xu L; Huang C; Deng J; Zhu H; Chen Z
    Gut Pathog; 2021 Apr; 13(1):22. PubMed ID: 33845868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Allweiss L; Volz T; Giersch K; Kah J; Raffa G; Petersen J; Lohse AW; Beninati C; Pollicino T; Urban S; Lütgehetmann M; Dandri M
    Gut; 2018 Mar; 67(3):542-552. PubMed ID: 28428345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus: new therapeutic perspectives.
    Lin CL; Yang HC; Kao JH
    Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
    Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A possible mechanism for low-level viremia occurrence in nucleos(t)ide analog-treated chronic hepatitis B patients].
    Wang LJ; Gu ZQ; Xu ZM; Chen XM; Lu FM
    Zhonghua Gan Zang Bing Za Zhi; 2021 Dec; 29(12):1151-1155. PubMed ID: 35045629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating hepatitis B virus cccDNA persistence in chronic infection.
    Lythgoe KA; Lumley SF; Pellis L; McKeating JA; Matthews PC
    Virus Evol; 2021 Jan; 7(1):veaa063. PubMed ID: 33732502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection.
    Butler EK; Gersch J; McNamara A; Luk KC; Holzmayer V; de Medina M; Schiff E; Kuhns M; Cloherty GA
    Hepatology; 2018 Dec; 68(6):2106-2117. PubMed ID: 29734472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B Gene Therapy Coming to Age.
    Soriano V
    AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.